65 results on '"Barua, I."'
Search Results
2. Herbicide Residues in Rice–Based Cropping Systems in Assam
- Author
-
Mahanta, Kaberi, Bora, N., Deka, J., Barua, I. C., Lichtfouse, Eric, Series Editor, Schwarzbauer, Jan, Series Editor, Robert, Didier, Series Editor, Sondhia, Shobha, editor, Choudhury, Partha P., editor, and Sharma, A.R., editor
- Published
- 2019
- Full Text
- View/download PDF
3. Benefits and harms of optical diagnosis by artificial intelligence in colonoscopy: a multicentre cohort study.
- Author
-
Halvorsen, N., Kudo, S. E., Barua, I., Misawa, M., Mori, K., Gulati, S., Hayee, B., Olabintan, O., Nilsen, J. A., Frigstad, S. O., East, J. E., Rastogi, A., Hassan, C., Kalager, M., Løberg, M., Holme, Ø., Haji, A., Bretthauer, M., and Yuichi, M.
- Subjects
ARTIFICIAL intelligence ,COLONOSCOPY ,COMPUTER-aided diagnosis ,COHORT analysis ,DIAGNOSIS - Abstract
A multicenter cohort study published in the journal Endoscopy examined the benefits and harms of using artificial intelligence with computer-aided diagnosis (CADx) in colonoscopy. The study found that CADx-assisted optical diagnosis could potentially save costs by reducing the need for histopathological evaluations. The CADx-assisted leave in-situ strategy, which involved not removing certain polyps, resulted in an average cost reduction of £17 per colonoscopy and a potential annual savings of £12 million in the UK. However, there was a small risk of misdiagnosing neoplastic polyps and a slight deviation from surveillance interval recommendations. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
4. SMART PILL TECHNOLOGY PROVIDES SAFE AND EFFECTIVE ASSESSMENT OF GASTROINTESTINAL FUNCTION IN PATIENTS WITH SYSTEMIC SCLEROSIS.
- Author
-
Barua, I., Fretheim, H., Didriksen, H., Carstens, M. N., Pesonen, M., Sarna, V., Midtvedt, Ø., Molberg, Ø., and Hoffmann-Vold, A. M.
- Published
- 2023
- Full Text
- View/download PDF
5. PREDICTION OF MORTALITY IN SSC-ILD DEPENDS ON DEFINITION OF ILD PROGRESSION.
- Author
-
Hoffmann-Vold, A. M., Petelytska, L., Fretheim, H., Barua, I., Becker, M. O., Bjørkekjær, H. J., Brunborg, C., Bruni, C., Diep, P. P., Dobrota, R., Durheim, M., Elhai, M., Jordan, S., Langballe, E., Midtvedt, Ø., Mihai, C., Molberg, Ø., and Distler, O.
- Published
- 2023
- Full Text
- View/download PDF
6. PROGRESSION OF INTERSTITIAL LUNG DISEASE IN SYSTEMIC SCLEROSIS DOES NOT PREDICT FURTHER PROGRESSION.
- Author
-
Hoffmann-Vold, A. M., Petelytska, L., Fretheim, H., Barua, I., Becker, M. O., Bjørkekjær, H. J., Brunborg, C., Bruni, C., Diep, P. P., Dobrota, R., Durheim, M., Elhai, M., Jordan, S., Langballe, E., Midtvedt, Ø., Mihai, C., Molberg, Ø., and Distler, O.
- Published
- 2023
- Full Text
- View/download PDF
7. SENSITIVITY TO CHANGE OF THE SCLEROID COMPARED TO THE UCLA GIT SCORE IN A COHORT OF SSC PATIENTS WITH LOWER GI SYMPTOMS.
- Author
-
Carstens, M. N., Garen, T., Didriksen, H., Fretheim, H., Barua, I., Knutsen, I. L., Karaaslan, T., Hatletveit, T., Pesonen, M. E., Midtvedt, Ø., Molberg, Ø., and Hoffmann-Vold, A. M.
- Published
- 2023
- Full Text
- View/download PDF
8. COMPARISON OF FOUR RISK STRATIFICATION MODELS FOR PREDICTION OF MORTALITY IN SSc-PAH IN THE EUSTAR COHORT.
- Author
-
Bjørkekjær, H. J., Bruni, C., Carreira, P., Airò, P., Aznar, C. P. Simeon, Truchetet, M. E., Giollo, A., Balbir-Gurman, A., Martin, M., Denton, C. P., Gabrielli, A., Fretheim, H., Barua, I., Bitter, H., Midtvedt, Ø., Garen, T., Broch, K., Andreassen, A., Tanaka, Y., and Riemekasten, G.
- Published
- 2023
- Full Text
- View/download PDF
9. RISK FACTORS FOR SSC-ILD PROGRESSION USING THE NEW PPF GUIDELINE AND INBUILD PF-ILD CRITERIA.
- Author
-
Hoffmann-Vold, A. M., Petelytska, L., Fretheim, H., Barua, I., Becker, M. O., Bjørkekjær, H. J., Brunborg, C., Bruni, C., Diep, P. P., Dobrota, R., Durheim, M., Elhai, M., Jordan, S., Langballe, E., Midtvedt, Ø., Mihai, C., Molberg, Ø., and Distler, O.
- Published
- 2023
- Full Text
- View/download PDF
10. Spectrophotometric Study of Complexation Equilibria Of Ni(II) with Ammonium-(2'-Amino-3'-Hydroxypyridyl-4'-Azo) Benzene-4-Arsonate and Determination of Ni(II) in Commonly Available Hydrogenated Oils
- Author
-
Y S Varma, S Barua, I Singh, B S Garg and R P Singh
- Subjects
lcsh:Q ,lcsh:Science - Abstract
Spectrophotometric Study of Complexation Equilibria Of Ni(II) with Ammonium-(2'-Amino-3'-Hydroxypyridyl-4'-Azo) Benzene-4-Arsonate and Determination of Ni(II) in Commonly Available Hydrogenated Oils
- Published
- 2015
11. Root-knot nematode Meloidogyne incognita reported from upland crops of Assam.
- Author
-
Neog, Pranjal P. and Barua, I. C.
- Subjects
ROOT-knot nematodes ,SOUTHERN root-knot nematode - Abstract
The article presents the discussion on root-knot nematode Meloidogyne incognita reporting from upland crops of Assam including the growing fields of each location in winter and summer seasons with the help of nematode sampling spade.
- Published
- 2021
- Full Text
- View/download PDF
12. Organic weed management in wet-seeded and transplanted aromatic rice
- Author
-
Sree, Yerradoddi Sindhu, Sarmah, Anjan K., and Barua, I.C.
- Published
- 2021
- Full Text
- View/download PDF
13. FECAL MICROBIOTA TRANSPLANTATION IN PATIENTS WITH SYSTEMIC SCLEROSIS AND LOWER GASTROINTESTINAL TRACT SYMPTOMS: DATA FROM THE RESSCUE RANDOMIZED CLINICAL TRIAL.
- Author
-
Fretheim, H., Barua, I., Carstens, M. N., Didriksen, H., Sarna, V., Lundin, K. E., Distler, O., Khanna, D., Volkmann, E., Midtvedt, Ø., Midtvedt, T., Dhainaut, A., Halse, A. K. H., Bakland, G., Olsen, I., Pesonen, M. E., Molberg, Ø., and Hoffmann-Vold, A. M.
- Published
- 2023
- Full Text
- View/download PDF
14. CHARACTERISTICS AND DISEASE COURSE OF UNTREATED PATIENTS WITH INTERSTITIAL LUNG DISEASE ASSOCIATED WITH SYSTEMIC SCLEROSIS IN A REAL-LIFE TWO-CENTER COHORT.
- Author
-
Scheidegger, M., Garaiman, A., Barua, I., Becker, M. O., Bjørkekjær, H. J., Bruni, C., Dobrota, R., Fretheim, H., Jordan, S., Maciukiewicz, M., Midtvedt, Ø., Mihai, C., Hoffmann-Vold, A. M., Distler, O., and Elhai, M.
- Published
- 2023
- Full Text
- View/download PDF
15. Appearance of new weeds in Punjab
- Author
-
Kaur, Simerjeet, Barua, I.C., Kaur, Tarundeep, Kaur, Navjyot, Kaul, Amit, and Bhullar, Makhan S.
- Published
- 2018
- Full Text
- View/download PDF
16. Long term application of herbicides on soil microbial demography in rice rice cropping sequence of North-East India
- Author
-
Mahanta, K., Dutta, P., Nath, D.J., Deka, J., Barua, I.C., Deka, N.C., and Sarma, A.K.
- Published
- 2017
- Full Text
- View/download PDF
17. Occurrence of fringe-rush in Kharif rice in Assam
- Author
-
Sarmah, Rupam, Barua, I.C., and Deb, Panna
- Published
- 2016
- Full Text
- View/download PDF
18. Effect of herbicides with or without paddy weeder on weeds in transplanted summer rice (Oryza sativa)
- Author
-
Rajkhowa, D.J., Deka, N.C., Borah, N., and Barua, I.C.
- Published
- 2007
19. Characteristics and disease course of untreated patients with interstitial lung disease associated with systemic sclerosis in a real-life two-centre cohort.
- Author
-
Scheidegger M, Boubaya M, Garaiman A, Barua I, Becker M, Bjørkekjær HJ, Bruni C, Dobrota R, Fretheim H, Jordan S, Midtvedt O, Mihai C, Hoffmann-Vold AM, Distler O, and Elhai M
- Subjects
- Humans, Antibodies, Antinuclear, Lung Diseases, Interstitial drug therapy, Lung Diseases, Interstitial etiology, Scleroderma, Systemic complications, Scleroderma, Systemic drug therapy, Pulmonary Fibrosis
- Abstract
Background: Interstitial lung disease (ILD) is the leading cause of death in systemic sclerosis (SSc). According to expert statements, not all SSc-ILD patients require pharmacological therapy., Objectives: To describe disease characteristics and disease course in untreated SSc-ILD patients in two well characterised SSc-ILD cohorts., Methods: Patients were classified as treated if they had received a potential ILD-modifying drug. ILD progression in untreated patients was defined as (1) decline in forced vital capacity (FVC) from baseline of ≥10% or (2) decline in FVC of 5%-9% associated with a decline in diffusing capacity for carbon monoxide (DLCO)≥15% over 12±3 months or (3) start of any ILD-modifying treatment or (4) increase in the ILD extent during follow-up. Multivariable logistic regression was performed to identify factors associated with non-prescription of ILD-modifying treatment at baseline. Prognostic factors for progression in untreated patients were tested by multivariate Cox regression., Results: Of 386 SSc-ILD included patients, 287 (74%) were untreated at baseline. Anticentromere antibodies (OR: 6.75 (2.16-21.14), p=0.001), limited extent of ILD (OR: 2.39 (1.19-4.82), p=0.015), longer disease duration (OR: 1.04 (1.00-1.08), p=0.038) and a higher DLCO (OR: 1.02 (1.01-1.04), p=0.005) were independently associated with no ILD-modifying treatment at baseline. Among 234 untreated patients, the 3 year cumulative incidence of progression was 39.9% (32.9-46.2). Diffuse cutaneous SSc and extensive lung fibrosis independently predicted ILD progression in untreated patients., Conclusion: As about 40% of untreated patients show ILD progression after 3 years and effective and safe therapies for SSc-ILD are available, our results support a change in clinical practice in selecting patients for treatment., Competing Interests: Competing interests: MS, MB, AG, IB, SJ, OM: none. MB: as consultancy relationship with and/or received research funding from and/or served as speaker for the following companies in the area of potential treatments for systemic sclerosis and its complications in the last three calendar years: GSK, Amgen, Novartis and outside of this research area: Vifor. HJB: grant/research support from: Janssen. CB: speakers bureau: Eli-Lilly, consultant of: Boehringer Ingelheim, grant/research support from: Gruppo Italiano Lotta alla Sclerodermia (GILS), European Scleroderma Trials and Research Group (EUSTAR), Foundation for research in Rheumatology (FOREUM), Scleroderma Clinical Trials Consortium (SCTC), Scleroderma Research Foundation (SRF). Educational grants from AbbVie and Wellcome Trust. Congress Support from: Boehringer Ingelheim. RD: speakers bureau/consultancy: Actelion, Boehringer-Ingelheim; grant/research support from: Pfizer, Actelion, Iten-Kohaut; congress participation support: Amgen, Otsuka. HF: speakers bureau: Boehringer Ingelheim, consultant of: Bayer, grant/research support from: GSK and Actelion, CM had consultancy relationship with and/or has served as a speaker for the following companies in the area of potential treatments for systemic sclerosis and its complications in the last three calendar years: Boehringer Ingelheim, Janssen, Roche. AMHV has received research funding and/or consulting fees and/or other remuneration from ARXX, Boehringer Ingelheim, Genentech, Janssen, Lilly, Medscape, Merck Sharp & Dohme, Roche. OD has/had relationships with the following companies in the area of potential treatments for systemic sclerosis and its complications in the last three calendar years: speaker fee: Bayer, Boehringer Ingelheim, Janssen, Medscape; consultancy fee: 4P-Pharma, Abbvie, Acceleron, Alcimed, Altavant Siences, Amgen, AnaMar, Arxx, AstraZeneca, Baecon, Blade, Bayer, Boehringer Ingelheim, Corbus, CSL Behring, Galapagos, Glenmark, Horizon, Inventiva, Kymera, Lupin, Miltenyi Biotec, Mitsubishi Tanabe, MSD, Novartis, Prometheus, Redxpharna, Roivant, Sanofi and Topadur; research grants: Kymera, Mitsubishi Tanabe. OD has/had relationships with the following companies in the area of dermatomyositis in the last three calendar years: consultancy fee: Pfizer (2021). ME: congress travel support from Janssen and Astrazeneca., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
20. Clinician Self-Disclosure in Palliative Care: Describing a Taxonomy and Proposing a Communication Tool.
- Author
-
Datta-Barua I and Hauser J
- Subjects
- Humans, Palliative Care, Self Disclosure, Communication, Disclosure, Hospice and Palliative Care Nursing
- Abstract
While patient self-disclosure is expected and necessary in the clinical setting, clinicians generally minimize their own self-disclosure, a practice largely guided by the boundaries of the fiduciary relationship. At the same time, many clinicians can recall a time when they made a self-disclosure to a patient, and it seemed to benefit the treatment relationship, if not the treatment itself. We reviewed literature from a variety of fields describing opinions, theories and limited data about the effects of clinician self-disclosure. Based on our findings, we posit that clinician self-disclosure has the potential to be a beneficial communication tool in palliative medicine, but like any intervention, it is not without risks. Thus, we propose a potential strategy to guide clinicians in thinking about self-disclosures.
- Published
- 2023
- Full Text
- View/download PDF
21. A Comparison of Risk Classification Systems of Colorectal Adenomas: A Case-Cohort Study.
- Author
-
Jodal HC, Wieszczy-Szczepanik P, Klotz D, Herfindal M, Barua I, Tag P, Helsingen LM, Refsum E, Holme Ø, Adami HO, Bretthauer M, Kalager M, and Løberg M
- Subjects
- Humans, Cohort Studies, Colonoscopy, Risk, Risk Factors, Adenoma epidemiology, Colorectal Neoplasms epidemiology, Colonic Polyps
- Abstract
Background & Aims: Because post-polypectomy surveillance uses a growing proportion of colonoscopy capacity, more targeted surveillance is warranted. We therefore compared surveillance burden and cancer detection using 3 different adenoma classification systems., Methods: In a case-cohort study among individuals who had adenomas removed between 1993 and 2007, we included 675 individuals with colorectal cancer (cases) diagnosed a median of 5.6 years after adenoma removal and 906 randomly selected individuals (subcohort). We compared colorectal cancer incidence among high- and low-risk individuals defined according to the traditional (high-risk: diameter ≥10 mm, high-grade dysplasia, villous growth pattern, or 3 or more adenomas), European Society of Gastrointestinal Endoscopy (ESGE) 2020 (high-risk: diameter ≥10 mm, high-grade dysplasia, or 5 or more adenomas), and novel (high-risk: diameter ≥20 mm or high-grade dysplasia) classification systems. For the different classification systems, we calculated the number of individuals recommended frequent surveillance colonoscopy and estimated number of delayed cancer diagnoses., Results: Four hundred and thirty individuals with adenomas (52.7%) were high risk based on the traditional classification, 369 (45.2%) were high risk based on the ESGE 2020 classification, and 220 (27.0%) were high risk based on the novel classification. Using the traditional, ESGE 2020, and novel classifications, the colorectal cancer incidences per 100,000 person-years were 479, 552, and 690 among high-risk individuals, and 123, 124, and 179 among low-risk individuals, respectively. Compared with the traditional classification, the number of individuals who needed frequent surveillance was reduced by 13.9% and 44.2%, respectively, and 1 (3.4%) and 7 (24.1%) cancer diagnoses were delayed using the ESGE 2020 and novel classifications., Conclusions: Using the ESGE 2020 and novel risk classifications will substantially reduce resources needed for colonoscopy surveillance after adenoma removal., (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
22. Speedometer for withdrawal time monitoring during colonoscopy: a clinical implementation trial.
- Author
-
Barua I, Misawa M, Glissen Brown JR, Walradt T, Kudo SE, Sheth SG, Nee J, Iturrino J, Mukherjee R, Cheney CP, Sawhney MS, Pleskow DK, Mori K, Løberg M, Kalager M, Wieszczy P, Bretthauer M, Berzin TM, and Mori Y
- Subjects
- Humans, Artificial Intelligence, Colonoscopy, Time Factors, Adult, Adenoma diagnosis, Colonic Polyps, Colorectal Neoplasms diagnosis
- Abstract
Objectives: Meticulous inspection of the mucosa during colonoscopy, represents a lengthier withdrawal time, but has been shown to increase adenoma detection rate (ADR). We investigated if artificial intelligence-aided speed monitoring can improve suboptimal withdrawal time., Methods: We evaluated the implementation of a computer-aided speed monitoring device during colonoscopy at a large academic endoscopy center. After informed consent, patients ≥18 years undergoing colonoscopy between 5 March and 29 April 2021 were examined without the use of the speedometer, and with the speedometer between 29 April and 30 June 2021. All colonoscopies were recorded, and withdrawal time was assessed based on the recordings in a blinded fashion. We compared mean withdrawal time, percentage of withdrawal time ≥6 min, and ADR with and without the speedometer., Results: One hundred sixty-six patients in each group were eligible for analyses. Mean withdrawal time was 9 min and 6.6 s (95% CI: 8 min and 34.8 s to 9 min and 39 s) without the use of the speedometer, and 9 min and 9 s (95% CI: 8 min and 45 s to 9 min and 33.6 s) with the speedometer; difference 2.3 s (95% CI: -42.3-37.7, p = 0.91). The ADRs were 45.2% (95% CI: 37.6-52.8) without the speedometer as compared to 45.8% (95% CI: 38.2-53.4) with the speedometer ( p = 0.91). The proportion of colonoscopies with withdrawal time ≥6 min without the speedometer was 85.5% (95% CI: 80.2-90.9) versus 86.7% (95% CI: 81.6-91.9) with the speedometer ( p = 0.75)., Conclusions: Use of speed monitoring during withdrawal did not increase withdrawal time or ADR in colonoscopy., Clinicaltrials.gov Identifier: NCT04710251.
- Published
- 2023
- Full Text
- View/download PDF
23. Impact of artificial intelligence on colorectal polyp detection for early-career endoscopists: an international comparative study.
- Author
-
Ainechi D, Misawa M, Barua I, Larsen SLV, Paulsen V, Garborg KK, Aabakken L, Tønnesen CJ, Løberg M, Kalager M, Kudo SE, Hotta K, Ohtsuka K, Saito S, Ikematsu H, Saito Y, Matsuda T, Itoh H, Mori K, Bretthauer M, and Mori Y
- Subjects
- Artificial Intelligence, Colonoscopy, Europe, Humans, Adenoma pathology, Colonic Polyps diagnosis, Colonic Polyps pathology, Colorectal Neoplasms diagnosis, Colorectal Neoplasms pathology
- Abstract
Background: Artificial intelligence (AI) for polyp detection is being introduced to colonoscopy, but there is uncertainty how this affects endoscopists' ability to detect polyps and neoplasms. We performed a video-based study to address whether AI improved the endoscopists' performance to detect polyps., Methods: We established a dataset of 200 colonoscopy videos (length 5 s; 100 without polyps and 100 with one polyp). About 33 early-career endoscopists (50-400 colonoscopies performed) from 10 European countries classified each video as either 'polyp present' or 'polyp not present'. The video assessment was performed twice with a four-week interval. The first assessment was performed without any AI tool, whereas the second was performed with an AI tool for polyp detection. The primary endpoint was early-career endoscopists' sensitivity to detect polyps. Gold standard for presence and histology of polyps were confirmed by two expert endoscopists and pathologists, respectively. McNemar's test was used for statistical significance., Results: There were 86 neoplastic and 14 non-neoplastic polyps (mean size 5.6 mm) in the 100 videos with polyps. Early-career endoscopists' sensitivity to detect polyps increased from 86.3% (95% confidence interval [CI]: 85.1-87.5%) to 91.7% (95%CI: 90.7-92.6%) with the AI aid ( p < .0001). Their sensitivity to detect neoplastic polyps increased from 85.4% (95% CI: 84.0-86.7%) to 92.1% (95%CI: 91.1-93.1%) with the AI aid ( p < .0001)., Conclusion: The polyp detection AI tool helped early-career endoscopists to increase their sensitivity to identify all polyps and neoplastic polyps during colonoscopy.
- Published
- 2022
- Full Text
- View/download PDF
24. Emergency hospital admissions, prognosis, and population mortality in Norway during the first wave of the Covid-19 epidemic.
- Author
-
Jodal HC, Juul FE, Barua I, Bretthauer M, Kalager M, Løberg M, and Emilsson L
- Subjects
- Communicable Disease Control, Emergency Service, Hospital, Hospital Mortality, Hospitalization, Hospitals, Humans, Prognosis, Retrospective Studies, COVID-19, Myocardial Infarction
- Abstract
Background: During the first wave of the Covid-19 epidemic, a national lockdown was established in Norway, and inhabitants were asked to contact healthcare only if absolutely necessary. We investigated hospital admissions and mortality due to non-Covid-19 disease during the lockdown compared to previous years., Methods: We compared the number of emergency admissions and in-hospital fatality for diagnoses probably unaffected (acute myocardial infarction, acute abdominal conditions, cerebrovascular diseases) and affected by the lockdown (infections, injuries) in the South-Eastern Health Region of Norway during weeks 12-22, 2020, compared to the mean of the same period in the years 2017-2019. We also compared population mortality March-May 2020, to the mean of the same period in years 2017-2019., Results: A total of 280,043 emergency admissions were observed; 20,911 admissions probably unaffected, and 30,905 admissions probably affected by the lockdown. Admissions due to diagnoses probably unaffected was reduced by 12% (95% confidence interval (CI) 9-15%), compared to 2017-2019. Admissions for diagnoses probably affected was reduced by 30% (95% CI 28-32%). There was a 34% reduction in in-hospital fatality due to acute myocardial infarction (95% CI 4-56%), 19% due to infections (95% CI 1-33%), and no change for the other diagnoses, compared to 2017-2019. The risk of in-hospital mortality to total mortality was lower for acute myocardial infarction (relative risk 0.85, 95% CI 0.73-0.99) and injuries (relative risk 0.83, 95% CI 0.70-0.98)., Conclusions: Even though fewer patients were admitted to hospital, there was no increase in in-hospital fatality or population mortality, indicating that those who were most in need still received adequate care.
- Published
- 2022
- Full Text
- View/download PDF
25. Cost-effectiveness of artificial intelligence for screening colonoscopy: a modelling study.
- Author
-
Areia M, Mori Y, Correale L, Repici A, Bretthauer M, Sharma P, Taveira F, Spadaccini M, Antonelli G, Ebigbo A, Kudo SE, Arribas J, Barua I, Kaminski MF, Messmann H, Rex DK, Dinis-Ribeiro M, and Hassan C
- Subjects
- Aged, Aged, 80 and over, Colonoscopy methods, Cost-Benefit Analysis, Humans, Mass Screening methods, Middle Aged, Artificial Intelligence, Colorectal Neoplasms diagnosis, Colorectal Neoplasms epidemiology, Colorectal Neoplasms prevention & control
- Abstract
Background: Artificial intelligence (AI) tools increase detection of precancerous polyps during colonoscopy and might contribute to long-term colorectal cancer prevention. The aim of the study was to investigate the incremental effect of the implementation of AI detection tools in screening colonoscopy on colorectal cancer incidence and mortality, and the cost-effectiveness of such tools., Methods: We conducted Markov model microsimulation of using colonoscopy with and without AI for colorectal cancer screening for individuals at average risk (no personal or family history of colorectal cancer, adenomas, inflammatory bowel disease, or hereditary colorectal cancer syndrome). We ran the microsimulation in a hypothetical cohort of 100 000 individuals in the USA aged 50-100 years. The primary analysis investigated screening colonoscopy with versus without AI every 10 years starting at age 50 years and finishing at age 80 years, with follow-up until age 100 years, assuming 60% screening population uptake. In secondary analyses, we modelled once-in-life screening colonoscopy at age 65 years in adults aged 50-79 years at average risk for colorectal cancer. Post-polypectomy surveillance followed the simplified current guideline. Costs of AI tools and cost for downstream treatment of screening detected disease were estimated with 3% annual discount rates. The main outcome measures included the incremental effect of AI-assisted colonoscopy versus standard (no-AI) colonoscopy on colorectal cancer incidence and mortality, and cost-effectiveness of screening projected for the average risk screening US population., Findings: In the primary analyses, compared with no screening, the relative reduction of colorectal cancer incidence with screening colonoscopy without AI tools was 44·2% and with screening colonoscopy with AI tools was 48·9% (4·8% incremental gain). Compared with no screening, the relative reduction in colorectal cancer mortality with screening colonoscopy with no AI was 48·7% and with screening colonoscopy with AI was 52·3% (3·6% incremental gain). AI detection tools decreased the discounted costs per screened individual from $3400 to $3343 (a saving of $57 per individual). Results were similar in the secondary analyses modelling once-in-life colonoscopy. At the US population level, the implementation of AI detection during screening colonoscopy resulted in yearly additional prevention of 7194 colorectal cancer cases and 2089 related deaths, and a yearly saving of US$290 million., Interpretation: Our findings suggest that implementation of AI detection tools in screening colonoscopy is a cost-saving strategy to further prevent colorectal cancer incidence and mortality., Funding: European Commission and Japan Society of Promotion of Science., Competing Interests: Declaration of interests YM declares consultancy work for and having equipment on loan from Olympus, and ownership interest in Cybernet System. AR has done consultancy work for and received research grants from Fujifilm, has been on advisory boards for and received speaker fees from Medtronic, has received speaker fees and research grants from Boston Scientific, and has done consultancy work for Cosmo Pharmaceuticals. MB has done consultancy work for Cybernet System. PS has done consultancy work for Medtronic, Olympus, Boston Scientific, Fujifilm, Salix Pharmaceuticals, and Lumendi; and has received research grants from Ironwood, Erbe, Docbot, Cosmo Pharmaceuticals, and CDx Labs. MFK has done consultancy and teaching work for Olympus, has equipment on loan from Fujifilm, and has done teaching work for Boston Scientific. HM has done consultancy work for and has equipment on loan from Olympus and Medtronic; and has done consultancy work for Boston Scientific. DKR has ownership interest in Satisfai Health and has done consultancy work for Olympus. MD-R has received a teaching grant from Olympus, a research grant from Fujifilm, and has done consultancy work for Medtronic. CH has done consultancy work for and has equipment on loan from Medtronic and Fujifilm, and has done consultancy work for Pentax. All other authors declare no competing interests., (Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
26. Real-Time Artificial Intelligence-Based Optical Diagnosis of Neoplastic Polyps during Colonoscopy.
- Author
-
Barua I, Wieszczy P, Kudo SE, Misawa M, Holme Ø, Gulati S, Williams S, Mori K, Itoh H, Takishima K, Mochizuki K, Miyata Y, Mochida K, Akimoto Y, Kuroki T, Morita Y, Shiina O, Kato S, Nemoto T, Hayee B, Patel M, Gunasingam N, Kent A, Emmanuel A, Munck C, Nilsen JA, Hvattum SA, Frigstad SO, Tandberg P, Løberg M, Kalager M, Haji A, Bretthauer M, and Mori Y
- Subjects
- Humans, Female, Male, Middle Aged, Aged, Diagnosis, Computer-Assisted methods, Sensitivity and Specificity, Colonic Neoplasms diagnosis, Colonic Neoplasms pathology, Colonic Neoplasms diagnostic imaging, Adult, Colonoscopy methods, Artificial Intelligence, Colonic Polyps pathology, Colonic Polyps diagnosis, Colonic Polyps diagnostic imaging
- Abstract
BACKGROUND: Artificial intelligence using computer-aided diagnosis (CADx) in real time with images acquired during colonoscopy may help colonoscopists distinguish between neoplastic polyps requiring removal and nonneoplastic polyps not requiring removal. In this study, we tested whether CADx analyzed images helped in this decision-making process. METHODS: We performed a multicenter clinical study comparing a novel CADx-system that uses real-time ultra-magnifying polyp visualization during colonoscopy with standard visual inspection of small (≤5 mm in diameter) polyps in the sigmoid colon and the rectum for optical diagnosis of neoplastic histology. After committing to a diagnosis (i.e., neoplastic, uncertain, or nonneoplastic), all imaged polyps were removed. The primary end point was sensitivity for neoplastic polyps by CADx and visual inspection, compared with histopathology. Secondary end points were specificity and colonoscopist confidence level in unaided optical diagnosis. RESULTS: We assessed 1289 individuals for eligibility at colonoscopy centers in Norway, the United Kingdom, and Japan. We detected 892 eligible polyps in 518 patients and included them in analyses: 359 were neoplastic and 533 were nonneoplastic. Sensitivity for the diagnosis of neoplastic polyps with standard visual inspection was 88.4% (95% confidence interval [CI], 84.3 to 91.5) compared with 90.4% (95% CI, 86.8 to 93.1) with CADx (P=0.33). Specificity was 83.1% (95% CI, 79.2 to 86.4) with standard visual inspection and 85.9% (95% CI, 82.3 to 88.8) with CADx. The proportion of polyp assessment with high confidence was 74.2% (95% CI, 70.9 to 77.3) with standard visual inspection versus 92.6% (95% CI, 90.6 to 94.3) with CADx. CONCLUSIONS: Real-time polyp assessment with CADx did not significantly increase the diagnostic sensitivity of neoplastic polyps during a colonoscopy compared with optical evaluation without CADx. (Funded by the Research Council of Norway [Norges Forskningsråd], the Norwegian Cancer Society [Kreftforeningen], and the Japan Society for the Promotion of Science; UMIN number, UMIN000035213.)
- Published
- 2022
- Full Text
- View/download PDF
27. Risk of hepato-pancreato-biliary cancer is increased by primary sclerosing cholangitis in patients with inflammatory bowel disease: A population-based cohort study.
- Author
-
Yu J, Refsum E, Helsingen LM, Folseraas T, Ploner A, Wieszczy P, Barua I, Jodal HC, Melum E, Løberg M, Blom J, Bretthauer M, Adami HO, Kalager M, and Ye W
- Subjects
- Bile Ducts, Intrahepatic, Cohort Studies, Humans, Pancreatic Neoplasms, Bile Duct Neoplasms epidemiology, Bile Duct Neoplasms etiology, Biliary Tract Neoplasms epidemiology, Carcinoma, Hepatocellular complications, Carcinoma, Hepatocellular etiology, Cholangiocarcinoma epidemiology, Cholangiocarcinoma etiology, Cholangitis, Sclerosing complications, Cholangitis, Sclerosing diagnosis, Cholangitis, Sclerosing epidemiology, Inflammatory Bowel Diseases complications, Inflammatory Bowel Diseases diagnosis, Inflammatory Bowel Diseases epidemiology, Liver Neoplasms complications, Liver Neoplasms etiology, Pancreatic Neoplasms complications, Pancreatic Neoplasms epidemiology
- Abstract
Background: There is continued uncertainty regarding the risks of hepato-pancreato-biliary cancers in patients with inflammatory bowel disease (IBD) with or without concomitant primary sclerosing cholangitis (PSC)., Objective: To give updated estimates on risk of hepato-pancreato-biliary cancers in patients with IBD, including pancreatic cancer, hepatocellular carcinoma, gall bladder cancer, and intra - and extrahepatic cholangiocarcinoma., Methods: In a population-based cohort study, we included all patients diagnosed with IBD in Norway and Sweden from 1987 to 2016. The cohort comprised of 141,960 patients, identified through hospital databases and the National Patient Register. Participants were followed through linkage to national cancer, cause of death, and population registries. We calculated absolute risk and standardized incidence ratios (SIRs) of hepato-pancreato-biliary cancers by PSC and other clinical characteristics., Results: Of the 141,960 IBD patients, 3.2% were diagnosed with PSC. During a median follow-up of 10.0 years, we identified 443 biliary tract cancers (SIR 5.2, 95% confidence interval [CI] 4.8-5.7), 161 hepatocellular carcinomas (SIR 2.4, 95% CI 2.0-2.7) and 282 pancreatic cancers (SIR 1.3, 95% CI 1.2-1.5). The relative risks were considerably higher in PSC-IBD patients, with SIR of 140 (95% CI 123-159) for biliary tract, 38.6 (95% CI 29.2-50.0) for hepatocellular, and 9.0 (95% CI 6.3-12.6) for pancreatic cancer. The SIRs were still slightly increased in non-PSC-IBD patients, compared to the general population. For biliary tract cancer, the cumulative probability at 25 years was 15.6% in PSC-IBD patients, and 0.4% in non-PSC-IBD patients., Conclusions: The dramatically increased risks of hepato-pancreato-biliary cancers in PSC-IBD patients support periodic surveillance for these malignancies. While much lower, the excess relative risks in non-PSC-IBD patients were not trivial compared to non-IBD related risk factors., (© 2022 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology.)
- Published
- 2022
- Full Text
- View/download PDF
28. Long-term colorectal cancer incidence and mortality after adenoma removal in women and men.
- Author
-
Jodal HC, Klotz D, Herfindal M, Barua I, Tag P, Helsingen LM, Refsum E, Holme Ø, Adami HO, Bretthauer M, Kalager M, and Løberg M
- Subjects
- Colonoscopy, Female, Follow-Up Studies, Humans, Incidence, Male, Risk Factors, Adenoma epidemiology, Adenoma surgery, Colorectal Neoplasms epidemiology, Colorectal Neoplasms surgery
- Abstract
Background: Women and men with colorectal adenomas are at increased risk of colorectal cancer and colonoscopic surveillance is recommended. However, the long-term cancer risk remains unknown., Aims: To investigate colorectal cancer incidence and mortality after adenoma removal in women and men METHODS: We identified all individuals who had adenomas removed in Norway from 1993 to 2007, with follow-up through 2018. We calculated standardized incidence ratios (SIR) and incidence-based mortality ratios (SMR) with 95% confidence intervals (CI) for colorectal cancer in women and men using the female and male population for comparison. We defined high-risk adenomas as ≥2 adenomas, villous component, or high-grade dysplasia., Results: The cohort comprised 40 293 individuals. During median follow-up of 13.0 years, 1079 women (5.5%) and 866 men (4.2%) developed colorectal cancer; 328 women (1.7%) and 275 men (1.3%) died of colorectal cancer. Colorectal cancer incidence was more increased in women (SIR 1.64, 95% CI 1.54-1.74) than in men (SIR 1.12, 95% CI 1.05-1.19). Colorectal cancer mortality was increased in women (SMR 1.13, 95% CI 1.02-1.26) and reduced in men (SMR 0.79, 95% CI 0.71-0.89). Women with high-risk adenomas had an increased risk of colorectal cancer death (SMR 1.37, 95% CI 1.19-1.57); women with low-risk adenomas (SMR 0.90, 95% CI 0.76-1.07) and men with high-risk adenomas had a similar risk (SMR 0.89, 95% CI 0.76-1.04), while men with low-risk adenomas had reduced risk (SMR 0.70, 95% CI 0.59-0.84)., Conclusions: After adenoma removal, women had an increased risk of colorectal cancer death, while men had reduced risk, compared to the general female and male populations. Sex-specific surveillance recommendations after adenoma removal should be considered., (© 2021 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
29. Mortality in Norway and Sweden during the COVID-19 pandemic.
- Author
-
Juul FE, Jodal HC, Barua I, Refsum E, Olsvik Ø, Helsingen LM, Løberg M, Bretthauer M, Kalager M, and Emilsson L
- Subjects
- Aged, Communicable Disease Control, Humans, Mortality, Norway epidemiology, Pandemics, SARS-CoV-2, Sweden epidemiology, COVID-19
- Abstract
Background: Norway and Sweden are similar countries in terms of socioeconomics and health care. Norway implemented extensive COVID-19 measures, such as school closures and lockdowns, whereas Sweden did not. Aims: To compare mortality in Norway and Sweden, two similar countries with very different mitigation measures against COVID-19. Methods: Using real-world data from national registries, we compared all-cause and COVID-19-related mortality rates with 95% confidence intervals (CI) per 100,000 person-weeks and mortality rate ratios (MRR) comparing the five preceding years (2015-2019) with the pandemic year (2020) in Norway and Sweden. Results: In Norway, all-cause mortality was stable from 2015 to 2019 (mortality rate 14.6-15.1 per 100,000 person-weeks; mean mortality rate 14.9) and was lower in 2020 than from 2015 to 2019 (mortality rate 14.4; MRR 0.97; 95% CI 0.96-0.98). In Sweden, all-cause mortality was stable from 2015 to 2018 (mortality rate 17.0-17.8; mean mortality rate 17.1) and similar to that in 2020 (mortality rate 17.6), but lower in 2019 (mortality rate 16.2). Compared with the years 2015-2019, all-cause mortality in the pandemic year was 3% higher due to the lower rate in 2019 (MRR 1.03; 95% CI 1.02-1.04). Excess mortality was confined to people aged ⩾70 years in Sweden compared with previous years. The COVID-19-associated mortality rates per 100,000 person-weeks during the first wave of the pandemic were 0.3 in Norway and 2.9 in Sweden. Conclusions: All-cause mortality in 2020 decreased in Norway and increased in Sweden compared with previous years. The observed excess deaths in Sweden during the pandemic may, in part, be explained by mortality displacement due to the low all-cause mortality in the previous year.
- Published
- 2022
- Full Text
- View/download PDF
30. Women require routine opioids to prevent painful colonoscopies: a randomised controlled trial.
- Author
-
Schult AL, Botteri E, Hoff G, Holme Ø, Bretthauer M, Randel KR, Gulichsen EH, El-Safadi B, Barua I, Munck C, Nilsen LR, Svendsen HM, and de Lange T
- Subjects
- Aged, Alfentanil adverse effects, Colonoscopy methods, Female, Humans, Middle Aged, Pain etiology, Pain prevention & control, Analgesics, Opioid adverse effects, Cecum
- Abstract
Background: Women are at high risk for painful colonoscopy. Pain, but also sedation, are barriers to colorectal cancer (CRC) screening participation. In a randomised controlled trial, we compared on-demand with pre-colonoscopy opioid administration to control pain in women at CRC screening age., Methods: Women, aged 55-79 years, attending colonoscopy at two Norwegian endoscopy units were randomised 1:1:1 to (1) fentanyl on-demand, (2) fentanyl prior to colonoscopy, or (3) alfentanil on-demand. The primary endpoint was procedural pain reported by the patients on a validated four-point Likert scale and further dichotomized for the study into painful (moderate or severe pain) and non-painful (slight or no pain) colonoscopy. Secondary endpoints were: willingness to repeat colonoscopy, adverse events, cecal intubation time and rate, and post-procedure recovery time., Results: Between June 2017 and May 2020, 183 patients were included in intention-to-treat analyses in the fentanyl on-demand group, 177 in the fentanyl prior to colonoscopy group, and 179 in the alfentanil on-demand group. Fewer women receiving fentanyl prior to colonoscopy reported a painful colonoscopy compared to those who were given fentanyl on-demand (25.2% vs. 44.1%, p < .001). There was no difference in the proportion of painful colonoscopies between fentanyl on-demand and alfentanil on-demand (44.1% vs. 39.5%, p = .40). No differences were observed for adverse events or any of the other secondary endpoints between the three groups., Conclusions: Fentanyl prior to colonoscopy provided better pain control than fentanyl or alfentanil on-demand. Fentanyl before colonoscopy should be recommended to all women at screening age. Trial registration: Clinicaltrials.gov (NCT01538550). Norwegian Medicines Agency (16/16266-13). EU Clinical Trials Register (EUDRACTNR. 2016-005090-13).
- Published
- 2021
- Full Text
- View/download PDF
31. Covid-19 transmission in fitness centers in Norway - a randomized trial.
- Author
-
Helsingen LM, Løberg M, Refsum E, Gjøstein DK, Wieszczy P, Olsvik Ø, Juul FE, Barua I, Jodal HC, Herfindal M, Mori Y, Jore S, Lund-Johansen F, Fretheim A, Bretthauer M, and Kalager M
- Subjects
- Humans, Pandemics, RNA, Viral, SARS-CoV-2, Treatment Outcome, COVID-19, Fitness Centers
- Abstract
Background: Closed fitness centers during the Covid-19 pandemic may negatively impact health and wellbeing. We assessed whether training at fitness centers increases the risk of SARS-CoV-2 virus infection., Methods: In a two-group parallel randomized controlled trial, fitness center members aged 18 to 64 without Covid-19-relevant comorbidities, were randomized to access to training at a fitness center or no-access. Fitness centers applied physical distancing (1 m for floor exercise, 2 m for high-intensity classes) and enhanced hand and surface hygiene. Primary outcomes were SARS-CoV-2 RNA status by polymerase chain reaction (PCR) after 14 days, hospital admission after 21 days. The secondary endpoint was SARS-CoV-2 antibody status after 1 month., Results: 3764 individuals were randomized; 1896 to the training arm and 1868 to the no-training arm. In the training arm, 81.8% trained at least once, and 38.5% trained ≥six times. Of 3016 individuals who returned the SARS-CoV-2 RNA tests (80.5%), there was one positive test in the training arm, and none in the no-training arm (risk difference 0.053%; 95% CI - 0.050 to 0.156%; p = 0.32). Eleven individuals in the training arm (0.8% of tested) and 27 in the no-training arm (2.4% of tested) tested positive for SARS-CoV-2 antibodies (risk difference - 0.87%; 95%CI - 1.52% to - 0.23%; p = 0.001). No outpatient visits or hospital admissions due to Covid-19 occurred in either arm., Conclusion: Provided good hygiene and physical distancing measures and low population prevalence of SARS-CoV-2 infection, there was no increased infection risk of SARS-CoV-2 in fitness centers in Oslo, Norway for individuals without Covid-19-relevant comorbidities., Trial Registration: The trial was prospectively registered in ClinicalTrials.gov on May 13, 2020. Due to administrative issues it was first posted on the register website on May 29, 2020: NCT04406909 ., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
32. Safety and efficacy of faecal microbiota transplantation by Anaerobic Cultivated Human Intestinal Microbiome (ACHIM) in patients with systemic sclerosis: study protocol for the randomised controlled phase II ReSScue trial.
- Author
-
Hoffmann-Vold AM, Fretheim HH, Sarna VK, Barua I, Carstens MN, Distler O, Khanna D, Volkmann ER, Midtvedt Ø, Didriksen H, Dhainaut A, Halse AK, Bakland G, Pesonen M, Olsen I, and Molberg Ø
- Subjects
- Anaerobiosis, Clinical Trials, Phase II as Topic, Double-Blind Method, Fecal Microbiota Transplantation, Humans, Los Angeles, Multicenter Studies as Topic, Pilot Projects, Randomized Controlled Trials as Topic, Treatment Outcome, Gastrointestinal Microbiome, Scleroderma, Systemic therapy
- Abstract
Introduction: In the multisystem inflammatory disorder systemic sclerosis (SSc), gastrointestinal tract (GIT) affliction is highly prevalent. There are no known disease modifying therapies and the negative impact is substantial. Aiming for a new therapeutic principle, and inspired by recent work showing associations between gut microbiota changes and GIT symptoms in SSc, we performed a pilot study on faecal microbiota transplantation (FMT) with the single-donor bacterial culture 'Anaerobic Cultivated Human Intestinal Microbiome (ACHIM)'. Motivated by positive pilot study signals, we designed the ReSScue trial as a phase II multicentre, placebo-controlled, randomised 20-week trial to evaluate safety and efficacy on lower GIT symptoms of FMT by ACHIM in SSc., Methods and Analyses: We aim to include 70 SSc participants with moderate to severe lower GIT symptoms, defined by the validated patient-reported University of California Los Angeles Scleroderma Clinical Trial Consortium GIT 2.0 2.0 questionnaire. The trial includes three parts. In part A1 (induction phase) lasting from week 0 to week 12, participants will be randomised 1:1 to repeat infusions of 30 mL ACHIM or placebo at week 0 and 2 by gastroduodenoscopy. In part A2, which is an 8-week subsequent maintenance phase, all study participants will receive 30 mL ACHIM at week 12 and followed until week 20 on continued blind. In part B, which will last until the last participant completes part A2, the participants will be followed through a maximum 16-week extended monitoring period, for longer-term data on safety and intervention effects. Primary endpoint is change from baseline to week 12 in UCLA GIT subscale scores of diarrhoea or bloating, depending on the worst symptom at baseline evaluated separately for each patient. Secondary endpoints are safety measures and changes in UCLA GIT scores (total, diarrhoea and bloating)., Ethics and Dissemination: This protocol was approved by the Northern Norwegian Committee for Medical Ethics. Study findings will be published., Trial Registration Number: NCT04300426; Pre-results., Protocol Version: V.3.1., Competing Interests: Competing interests: A-MH-V: Actelion, ARXX, Bayer, Boehringer Ingelheim, Medscape, Merck Sharp & Dohme, Lilly and Roche. OD: Abbvie, Acceleron Pharma, Amgen, AnaMar, Bayer, Boehringer Ingelheim, Catenion, Drug Development International, CSL Behring, ChemomAb, GSK, Horizon (Curzion) Pharmaceuticals, Inventiva, Italfarmaco, iQvia, Lilly, Medac, Medscape, Mitsubishi Tanabe Pharma, MSD, Novartis, Pfizer, Roche, Sanofi, Serodapharm, Target Bio Science and UCB in the area of potential treatments of scleroderma and its complications. In addition, OD has a patent mir-29 for the treatment of systemic sclerosis issued (US8247389, EP2331143). DK: Abbvie, Actelion/Janssen, Acceleron Pharma, Amgen, Bayer, Boehringer Ingelheim, CSL Behring, GSK, Horizon Pharmaceuticals, Mitsubishi Tanabe Pharma, Pfizer, Roche, Sanofi, United Therapeutics. DK is chief medical officer of Eicos Sciences. ERV: Disclosures unrelated to the manuscript: Grants (Corbus, Forbius, Boehringer Ingelheim); Consulting fees (Boehringer Ingelheim). ØMi: Son of owner of ACHIM., (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2021
- Full Text
- View/download PDF
33. Colorectal polyp characterization with endocytoscopy: Ready for widespread implementation with artificial intelligence?
- Author
-
Barua I, Mori Y, and Bretthauer M
- Subjects
- Humans, Artificial Intelligence standards, Colonic Polyps pathology, Colonoscopy methods, Colorectal Neoplasms pathology, Endoscopy methods
- Abstract
Endocytoscopy provides an in-vivo visualization of nuclei and micro-vessels at the cellular level in real-time, facilitating so-called "optical biopsy" or "virtual histology" of colorectal polyps/neoplasms. This functionality is enabled by 520-fold magnification power with endocytoscopy and recent breakthroughs in artificial intelligence (AI) allowing a great advance in endocytoscopic imaging; interpretation of images is now fully supported by AI tool which outputs predictions of polyp histopathology during colonoscopy. The advantage of the use of AI during optical biopsy can be appreciated especially by non-expert endoscopists who to increase performance. This paper provides an overview of the latest evidence on colorectal polyp characterization with endocytoscopy combined with AI and identify the barriers to its widespread implementation., (Copyright © 2020 Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
34. Artificial intelligence for polyp detection during colonoscopy: a systematic review and meta-analysis.
- Author
-
Barua I, Vinsard DG, Jodal HC, Løberg M, Kalager M, Holme Ø, Misawa M, Bretthauer M, and Mori Y
- Subjects
- Artificial Intelligence, Colonoscopy, Humans, Prospective Studies, Adenoma diagnosis, Colonic Polyps diagnostic imaging
- Abstract
Background: Artificial intelligence (AI)-based polyp detection systems are used during colonoscopy with the aim of increasing lesion detection and improving colonoscopy quality., Patients and Methods: We performed a systematic review and meta-analysis of prospective trials to determine the value of AI-based polyp detection systems for detection of polyps and colorectal cancer. We performed systematic searches in MEDLINE, EMBASE, and Cochrane CENTRAL. Independent reviewers screened studies and assessed eligibility, certainty of evidence, and risk of bias. We compared colonoscopy with and without AI by calculating relative and absolute risks and mean differences for detection of polyps, adenomas, and colorectal cancer., Results: Five randomized trials were eligible for analysis. Colonoscopy with AI increased adenoma detection rates (ADRs) and polyp detection rates (PDRs) compared to colonoscopy without AI (values given with 95 %CI). ADR with AI was 29.6 % (22.2 % - 37.0 %) versus 19.3 % (12.7 % - 25.9 %) without AI; relative risk (RR] 1.52 (1.31 - 1.77), with high certainty. PDR was 45.4 % (41.1 % - 49.8 %) with AI versus 30.6 % (26.5 % - 34.6 %) without AI; RR 1.48 (1.37 - 1.60), with high certainty. There was no difference in detection of advanced adenomas (mean advanced adenomas per colonoscopy 0.03 for each group, high certainty). Mean adenomas detected per colonoscopy was higher for small adenomas (≤ 5 mm) for AI versus non-AI (mean difference 0.15 [0.12 - 0.18]), but not for larger adenomas (> 5 - ≤ 10 mm, mean difference 0.03 [0.01 - 0.05]; > 10 mm, mean difference 0.01 [0.00 - 0.02]; high certainty). Data on cancer are unavailable., Conclusions: AI-based polyp detection systems during colonoscopy increase detection of small nonadvanced adenomas and polyps, but not of advanced adenomas., Competing Interests: M. Misawa and Y. Mori have each provided consultancy to and received an honorarium from Olympus. The remaining authors declare no conflicts of interest., (Thieme. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
35. National screening programme for colorectal cancer.
- Author
-
Barua I, Berset IP, Hære P, Wensaas KA, and Bretthauer M
- Subjects
- Humans, Mass Screening, Occult Blood, Colorectal Neoplasms diagnosis, Colorectal Neoplasms epidemiology, Early Detection of Cancer
- Published
- 2020
- Full Text
- View/download PDF
36. The Therapeutic Utility of the Pregnant Palliative Care Physician: A Case Series.
- Author
-
Datta-Barua I, O'Brien K, and Vermylen J
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Pregnancy, United States, Hospice Care psychology, Palliative Care psychology, Patient Satisfaction, Physician-Patient Relations, Physicians psychology, Pregnant Women psychology, Terminal Care psychology
- Abstract
Women physicians are becoming more numerous, with the majority of active hospice and palliative medicine physicians under the age of 50 being women. While this trend has appropriately led to discussions of supporting, recruiting, and retaining women physicians, there is little literature about the effect of women physicians on patients. In particular, little has been written about the effect of a physician's pregnancy. Drawing on psychotherapeutic literature, the authors present seven cases illustrating how pregnancy of the palliative care physician affects patients and families. By recognizing the responses of patients and families and understanding the underlying meaning of the pregnancy, which drives those responses, palliative care physicians can utilize the pregnancy to select therapeutic interventions for the patient and family.
- Published
- 2019
- Full Text
- View/download PDF
37. Four Communication Skills from Psychiatry Useful in Palliative Care and How to Teach Them.
- Author
-
Datta-Barua I and Hauser J
- Subjects
- Adult, Humans, Male, Middle Aged, United States, Communication, Education, Medical methods, Health Personnel education, Palliative Care methods, Psychiatry methods
- Abstract
Palliative care and psychiatry share a number of the same priorities, including careful attention to communication skill development. In this article, we identify 4 communication skills helpful in both fields: (1) attending to countertransference, (2) practicing active listening and active reflection, (3) remaining silent and neutral, and (4) naming the emotion. We then describe strategies for teaching these skills., (© 2018 American Medical Association. All Rights Reserved.)
- Published
- 2018
- Full Text
- View/download PDF
38. Evaluation of intestinal tuberculosis by multi-slice computed tomography enterography.
- Author
-
Zhao J, Cui MY, Chan T, Mao R, Luo Y, Barua I, Chen M, Li ZP, and Feng ST
- Subjects
- Adolescent, Adult, Aged, Child, Diagnosis, Differential, Female, Humans, Male, Middle Aged, Peritonitis, Tuberculous diagnostic imaging, Retrospective Studies, Young Adult, Tomography, X-Ray Computed methods, Tuberculosis, Gastrointestinal diagnostic imaging
- Abstract
Background: Multi-slice computed tomography enterography (MSCTE) is now widely used to diagnose and monitor intestinal disease. Preliminary studies suggest that MSCTE may be useful in detecting intestinal tuberculosis (ITB). We sought to assess the use of MSCTE for the diagnosis of ITB in our medical center., Methods: In this retrospective study, 15 patients (11 males and 4 females, 6 to 65 years old) were enrolled and diagnosed with ITB by MSCTE. Diagnosis were confirmed by pathology or clinical criteria. Two experienced abdominal radiologists evaluated the images and defined the location, number, shape, edge, surrounding tissue alterations of ITB and other associated changes in the peritoneum, mesentery and solid abdominal organs., Results: The interval between the onset of symptoms and diagnosis varied from 20 days to 10 years. The most common symptom was abdominal pain (80 %). The ileocecum was the most common site affected by ITB (87 %). Morphological MSCTE findings were variable and included multi-segmental symmetric intestinal mural thickening found in 6 patients (40 %), solid masses found in 9 patients (60 %), and enlarged lymph nodes (LNs) found in 13 (87 %) patients. Non-enhancing central necrosis and rim enhancement were noted in 10 patients (67 %)., Conclusions: Characteristic MSCTE findings of ITB include solid mass or multi-segmental symmetric mural thickening involving the ileocecal area and rim enhanced LNs. Knowledge of these features in combination with a high index of suspicion can be useful in early diagnosis of ITB.
- Published
- 2015
- Full Text
- View/download PDF
39. A survey of prognosis discussions held by health-care providers who request palliative care consultation.
- Author
-
Chang A, Datta-Barua I, McLaughlin B, and Daly B
- Subjects
- Adult, Aged, Communication, Female, Humans, Male, Medical Staff, Hospital, Middle Aged, Ohio, Prognosis, Referral and Consultation, Surveys and Questionnaires, United States, Young Adult, Nurse-Patient Relations, Palliative Care, Physician-Patient Relations, Truth Disclosure
- Abstract
Background: Patient misunderstandings about prognosis may be related to lack of communication., Aim: This study aimed to examine prognosis discussions held with hospitalized patients for whom palliative care consultations were requested, and if prognosis discussions did not occur, to explore why not., Design: This was a survey conducted over the telephone from a convenience sample of health-care providers who requested palliative care consultations. Respondents were asked about whether prognosis had been discussed with the patient and the topics addressed., Participants: A total of 65 health-care providers who called to request a consultation from the palliative care team in a large academic medical center in the United States., Results: Of the 65 responses, 45 (69.2%) subjects reported that a prognosis discussion had occurred, while 15 (23.1%) reported that a prognosis discussion had not taken place. Among the surveys reporting a prognosis discussion, a majority of providers responded that most aspects of prognosis were discussed, with the exceptions of life expectancy, survival rates/statistics, and psychosocial concerns. When the prognosis discussion had not occurred, the most common reasons for omitting the prognosis discussion included difficulty in determining prognosis, the perception that the patient already knew his or her prognosis, and the belief that the prognosis discussion was better suited for a different specialty., Conclusions: The results of this study highlight the uncertainty that primary team providers in the academic hospital environment have with prognostication, which is a complex process for which this set of providers, composed primarily of medical trainees and nurses, may not have had sufficient training.
- Published
- 2014
- Full Text
- View/download PDF
40. [Is introducing grades the way to go?].
- Author
-
Slørdahl JT and Barua I
- Subjects
- Humans, Education, Medical, Undergraduate standards, Educational Measurement methods
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.